Image Source: HCT website
Holista Colltech has secured trademark approval for sale of Natshield™ sanitisers in China.
The trademark is valid for 10 years, with the Trademark Class 5 category relating mainly to pharmaceuticals and other preparations for medical or veterinary purposes.
Holista does not require additional approvals to commercialise its NatshieldTMaerosol disinfectant and M3 System for industrial applications in the large and lucrative Chinese market.
In what comes as a significant milestone, Holista Colltech Limited (ASX:HCT) has secured trademark labelling approval for its Natshield™ sanitiser brand in China. The trademark is valid for 10 years and paves the way for Holista to start selling its innovative solution in the large Chinese market.
The health & wellness company announced the significant development on 16 September, giving a leg up to its initiatives on the infection control solutions front.
The approval granted by the Chinese patent office – China National Intellectual Property Administration (CNIPA) – is for Trademark Class 5, a category relating mainly to pharmaceuticals and other preparations for medical or veterinary purposes.
The trademark provides the Company brand name protection as it gears up to launch NatshieldTM aerosol disinfectant and M3 System for industrial applications in the Chinese market. Holista, in its latest update, has indicated that no further approvals are needed for commercialisation purposes.
Furthermore, Guangzhou Sinbio Cosmetic Co Ltd, Holista’s Chinese business partner, plans to soon kick off the process of applying for medical use standards for products to be sold into hospitals.
The M3 system can be used in a building’s heating ventilation and air conditioning (HVAC) system to control airborne viruses.
The system automatically dispenses a unique all-natural aerosol sanitiser that works against SARS-CoV-2, the virus that causes COVID-19 as per the Company.
There are numerous cases documented in Australia and around the world where people have become infected with COVID-19 through a building’s central ventilation system.
This makes offices, hotels, malls and other large buildings a high-risk area in catching the virus.
Having a safe and effective solution like M3 will be invaluable in keeping employees and members of the public safe.
Given the vast number of buildings in China, the market represents a very lucrative opportunity for Holista.
Holista’s Infection Control Solutions division is witnessing a positive outlook as the pandemic drives demand for all-natural sanitisers that are gentle on the skin despite repeated use.
In addition, the Company is experiencing growing sales of its NatShield™ sanitisers following the successful restructure of its global distribution partner iGalen. Significantly, the ongoing recovery in iGalen is expected to provide an additional boost to the sales growth momentum.
Meanwhile, the Company is exploring further opportunities for its COVID-19 test kits. Holista’s decision to expand its suite of products to include the COVID-19 test kits is expected to further ramp up the pace of growth.
HCT traded at AU$0.060 on 16 September 2021, up 3.448% from its last closing price.
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and